Navigation Links
Avalon Pharmaceuticals Announces Positive Interim Results For,AVN944 Phase I Trial

the slides, please choose the 'listen via phone' option to view the slides in real time as there is a 30 second delay otherwise. The conference call replay will be available through August 15, 2007 on Avalon's website (www.avalonrx.com).

About Avalon Pharmaceuticals

Avalon Pharmaceuticals is a biopharmaceutical company focused on the discovery and development of potential first-in-class cancer therapeutics. Avalon has a lead product in Phase I clinical development (AVN944), preclinical programs to develop inhibitors for the Beta-catenin and Aurora pathways, discovery programs for Survivin and Myc pathway inhibitors, and value generating partnerships with Merck, MedImmune, Medarex, and Novartis. By utilizing AvalonRx(R) our platform technology, based upon the proprietary use of large-scale gene expressions, we are uniquely positioned to develop therapeutics focused on pathways that have historically been characterized as "undruggable". Avalon was established in 1999 and is headquartered in Germantown, Md.

About AvalonRx(R)

AvalonRx(R) is a comprehensive, innovative and proprietary suite of technologies based upon large-scale gene expression analysis. This platform facilitates drug discovery by expanding the range of therapeutic targets for drug intervention, including targets and target pathways frequently considered intractable using conventional HTS approaches, allows more informed decisions about which compounds to advance towards clinical trials, and facilitates drug development through identification of biomarkers of efficacy that can stratify patients or provide early indicators of response.

Safe Harbor Statement

This announcement contains, in addition to historical information, certain forward-looking statements that involve risks and uncerta
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Avalon Updates the AVN944 Phase I Hematologic Malignancies Trial
2. Avalon Pharmaceuticals to Present at the American Association for Cancer Research 2007 Annual Meeting
3. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
7. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
8. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
9. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
10. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
11. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
Post Your Comments:
(Date:7/21/2014)... , July 21, 2014 Integrity Applications, ... of the GlucoTrack ® model DF-F noninvasive ... has entered, through its wholly-owned subsidiary, Integrity Applications ... the manufacturing arm of Acer Inc.  Pursuant to ... service (on a non-exclusive basis) the GlucoTrack Model ...
(Date:7/21/2014)... Calif. , July 21, 2014   ... a biopharmaceutical company leading the discovery and development ... the U.S. Food & Drug Administration (FDA) has ... stranded, chemically modified oligonucleotide that binds to and ... therapeutic for the treatment of Alport syndrome, a ...
(Date:7/21/2014)... -- An International Trade Commission (ITC) ruling issued Friday held ... Taiwanese device manufacturer APEX continues to infringe ResMed patents ... is the innovation leader and pioneer in designing and ... "Our research and development teams are constantly ... comfort, performance and efficacy," said David Pendarvis , ...
Breaking Medicine Technology:Integrity Applications, Inc. Enters into Manufacturing Agreement with Wistron Corp. 2Integrity Applications, Inc. Enters into Manufacturing Agreement with Wistron Corp. 3Regulus Receives Orphan Drug Designation for RG-012, a microRNA Therapeutic for the Treatment of Alport Syndrome 2Regulus Receives Orphan Drug Designation for RG-012, a microRNA Therapeutic for the Treatment of Alport Syndrome 3Regulus Receives Orphan Drug Designation for RG-012, a microRNA Therapeutic for the Treatment of Alport Syndrome 4Regulus Receives Orphan Drug Designation for RG-012, a microRNA Therapeutic for the Treatment of Alport Syndrome 5ITC Rules Redesigned APEX Humidifier Still Infringes ResMed Patents 2
... a clinico-molecular informatics company, today announced the commercialization ... lines that translate patient-specific molecular and genomic data, ... more effective drug choices for patients. ... drastically and clinical data becoming increasingly accessible, today,s ...
... /PR Newswire-Asia/ -- Global Pharm Holdings Group, Inc. ... growing vertically integrated pharmaceutical company engaged in the ... processing, and herbal cultivation and sales in China ... Shandong provinces, today announced the appointment of Mr. ...
Cached Medicine Technology:MolecularHealth to Introduce Knowledge-Driven Solutions that Enhance Drug Safety and Enable Molecularly-Guided Treatment Decision Support 2MolecularHealth to Introduce Knowledge-Driven Solutions that Enhance Drug Safety and Enable Molecularly-Guided Treatment Decision Support 3Global Pharm Holdings Group, Inc. Strengthens its Board by Adding a Non-Executive Director 2Global Pharm Holdings Group, Inc. Strengthens its Board by Adding a Non-Executive Director 3
(Date:7/22/2014)... Bar, CA (PRWEB) July 22, 2014 ... leading provider of enterprise Time and Attendance / ... in Iowa, a NOVAtime 3000 customer since 2007, ... self-hosted, licensed version of NOVAtime’s state-of-the-art, web-based time ... Lutheran Services in Iowa (LSI) is a human ...
(Date:7/22/2014)... Orem, UT (PRWEB) July 22, 2014 Most people ... first is a weak appetite and the second is a fast ... CB-1 Weight Gainer provides ways to help fight these ... lack of appetite. There are people out there who just can’t ... take bites and then they are full. The cause of this ...
(Date:7/21/2014)... designed to target and kill cancer cells could boost ... and help avoid amputation, a new study reports. , ... the effectiveness of a genetically engineered version of the ... use of the virus alongside isolated limb perfusion chemotherapy ... arm or leg as an alternative to amputation ...
(Date:7/21/2014)... July 22, 2014 iFitDress.com, a famous ... women, has announced its exclusive collection of 2014 ... a promotion for its brand new gowns. , iFitDress.com ... the current market. Its sales boomed in the recent ... products, but also because of the amicable services offered ...
(Date:7/21/2014)... July 21, 2014 The League of ... 1199SEIU United Healthcare Workers East (“1199SEIU”) today announced a ... issues facing healthcare providers and their employees. , ... require ratification by League and 1199SEIU members, employee wages ... addition, all existing worker benefits, including healthcare coverage with ...
Breaking Medicine News(10 mins):Health News:Lutheran Services in Iowa Upgrades to NOVAtime 4000 Time and Attendance / Workforce Management Solution; Benefits from Labor Costing Functionality 2Health News:Lutheran Services in Iowa Upgrades to NOVAtime 4000 Time and Attendance / Workforce Management Solution; Benefits from Labor Costing Functionality 3Health News:CB-1 Weight Gainer Provides Two Tips to Help Customers Gain Weight 2Health News:Viral therapy could boost limb-saving cancer treatment 2Health News:Viral therapy could boost limb-saving cancer treatment 3Health News:iFitDress.com: 2014 Glitter Evening Dresses For Worldwide Clients 2Health News:League of Voluntary Hospitals and Homes and 1199SEIU Reach New Four-Year Collective Bargaining Agreement 2Health News:League of Voluntary Hospitals and Homes and 1199SEIU Reach New Four-Year Collective Bargaining Agreement 3
... 11 (HealthDay News) -- Low oxygen supply (hypoxia) increases the ... a severe traumatic brain injury (TBI), a new study finds. ... with TBI, most of whom had bleeding within the brain ... fared poorly, suffering severe disability, dying or being in a ...
... SAN FRANCISCO, CA NOVEMBER 11, 2011 ... demonstrated that cryoplasty post-dilitation compared to conventional balloon ... the risk of in-stent restenosis (ISR). Results from ... the 23rd Annual Transcatheter Cardiovascular Therapeutics (TCT) scientific ...
... FRIDAY, Nov. 11 (HealthDay News) -- Repeated bouts of ... pain and infertility, a new study says. Pelvic inflammatory ... is marked by inflammation of the reproductive organs. The condition ... year and one in 10 of them becomes infertile, according ...
... SAN FRANCISCO, CA NOVEMBER 11, 2011 ... de novo coronary artery lesions showed a significantly ... to paclitaxel-eluting stents with permanent polymers. ... at the 23rd annual Transcatheter Cardiovascular Therapeutics (TCT) ...
... the past 100 years, the Haber-Bosch process has been used ... the manufacture of fertilizer. Despite the longstanding reliability of the ... works. But now a team of chemists, led by Patrick ... how the ammonia is formed. Their findings are published in ...
... FRIDAY, Nov. 11 (HealthDay News) -- Age-related declines in ... to a new study. "The more income and ... be," co-author Virginia Richardson, a professor of social work ... release. The researchers analyzed data from roughly 6,500 ...
Cached Medicine News:Health News:Results of the COBRA trial reported at TCT 2011 2Health News:STD Complication May Double Infertility Risk 2Health News:Results of the NEXT clinical trial Reported at TCT 2011 2Health News:Researchers gain insight into 100-year-old Haber-Bbosch process 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: